Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 


Pacific Edge signs Cxbladder agreement with MultiPlan

Pacific Edge signs Cxbladder agreement with national provider network MultiPlan in the US

Pacific Edge announced today that it has entered into a contractual agreement with MultiPlan, Inc. for diagnostics laboratory testing. The agreement includes Pacific Edge’s participation in the MultiPlan, PHCS and PHCS Savility Networks.

The agreement is the fourth signed with national provider networks by Pacific Edge since October 2013 and is another step in the Company’s commercial roll-out of Cxbladder in the United States, the world’s largest healthcare market. The agreement with MultiPlan in addition to the agreements with FedMed,
Americas Choice Provider Network, and Stratose makes Cxbladder available to a significant proportion of US residents.

Pacific Edge Chief Executive Officer David Darling says national and regional provider networks are a key component in the commercial fabric ensuring that healthcare providers and technology suppliers are paid by healthcare payers for treatment provided to patients.

“Our participation in these networks will give a large number of Americans access to Cxbladder and its positive benefits as a quick, cost effective, non-invasive and highly accurate cancer detection test that is particularly appealing to US healthcare professionals, patients, and insurers.”

Pacific Edge’s agreement with MultiPlan will give MultiPlan’s participating providers and its clients’ members access to Cxbladder. Approximately 900,000 providers participate in MultiPlan’s provider networks and an estimated 68 million consumers have access to one or more of these networks.

Pacific Edge through its wholly owned subsidiary Pacific Edge Diagnostics USA (PEDUSA) has launched Cxbladder in the US and is processing samples collected using its proprietary Urine Sampling System at its custom built, CAP accredited laboratory in Hershey, Pennsylvania.

“Our sales and marketing teams are now focussed on the urologists and clinicians who are treating the largest number of bladder cancer patients to ensure they fully understand the value and benefits that Cxbladder provides to them and their patients” says Jackie Walker, Chief Executive Officer of PEDUSA.

“In addition we are advancing relationships with large commercial payers and the Centre for Medicare and Medicaid Services (CMS), which provides healthcare insurance for 100 million people or nearly a third of the American population. Progress is being made with key customer segments including Integrated Healthcare Systems, the Veterans Administration (VA), and Large Urology Groups (LUGS),

who are the point of contact for many patients presenting with haematuria blood in the urine) which is an early indicator of possible bladder cancer.”

More than one million Americans a year undergo medical investigation for potential bladder cancer at an estimated cost in excess of US$1 billion. Bladder cancer is one of the most expensive cancers to treat.

The very high recurrence rate of this disease, requiring some patients to receive expensive monitoring for the rest of their lives, causes bladder cancer to have the highest total medical costs of any cancer from detection to death. In the US, the total medical cost approaches US$220,000 per patient.

Ends

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

What Winter? Temperature Records Set For June 20-22

The days around the winter soltice produced a number of notably warm tempertaures. More>>

Conservation Deal: New Kākāpō Recovery Partnership Welcomed

Conservation Minister Maggie Barry says the new kakapo recovery partnership between DOC and Meridian Energy is great news for efforts to save one of New Zealand’s most beloved birds. More>>

ALSO:

Tech Sector Report: Joyce Warns Asian Tech Investors View NZ As Hobbits And Food

Speaking in Wellington at the launch of a report showcasing the value of the technology sector to the New Zealand economy, Joyce said more had to be done to tell the country's technology stories overseas. More>>

ALSO:

Mediaglommeration: APN Gets OIO Approval For Demerger Plan

APN News & Media has received Overseas Investment Office approval for its plan to split out its NZME unit ahead of a potential merger with rival Fairfax Media's New Zealand operations. More>>

New Paper: Ninety-Day Trial Period Has No Impact On Firms' Hiring

The introduction of a 90-day trial period has had no impact on hiring by New Zealand companies although they are now in widespread use, according to researchers at Motu Economic and Public Policy Research. More>>

ALSO:

Corrections: Serco Exits Equity Stake, Remains As Operator

Serco has sold its equity stake in the company that holds the contract to design, build and run Wiri Prison in South Auckland but continues as sub-contractor to operate the facility. More>>

GDP: NZ Economy Grows Faster-Than-Forecast 0.7%

New Zealand's economy grew at a faster pace than expected in the first quarter of 2016 as construction expanded at the quickest rate in two years. The kiwi dollar jumped after the data was released. More>>

ALSO:

Get More From Scoop

 
 
 
 
 
 
 
 
 
Business
Search Scoop  
 
 
Powered by Vodafone
NZ independent news